Clinical Trials Logo

Penile Neoplasms Malignant clinical trials

View clinical trials related to Penile Neoplasms Malignant.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03418480 Completed - Clinical trials for Head and Neck Neoplasm

HARE-40: HPV Anti-CD40 RNA vaccinE

HARE-40
Start date: April 11, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

HARE-40 is a phase I/II vaccine dose escalation study with two different arms: Arm 1A will perform intrapatient dose escalation in patients with previously treated HPV16+ Head & Neck Cancer using two dose cohorts to establish a safe, tolerable and recommended dose of HPV vaccine. Arm 1B will perform intrapatient dose escalation in patients with advanced HPV16+ cancer (head and neck, anogenital, penile, cervical and other) using a single cohort to establish a safe, tolerable and recommended dose of HPV vaccine.